

Abbott PJ, Weller SB, Delaney HD, Moore BA (1998). Community reinforcement approach in the treatment of opiate addicts. *American Journal of Drug and Alcohol Abuse*, 24, 730.

ACMD (1988). AIDS and Drug Misuse: Part 1. Report by the UK Advisory Council on the Misuse of Drugs. London: HMSO.

Alter MJ (2002). Prevention of spread of hepatitis C. *Hepatology*, 36, 938.

Alterman A, Cacciola J (1991). The antisocial personality disorder diagnosis in substance abusers: problems and issues. *Journal of Nervous and Mental Disease*, 179, 401–409.

Alterman A, McLellan A, Shifman R (1993). Do substance abuse patients with more psychopathology receive more treatment? *Journal of Nervous and Mental Disease*, 181, 576–582.

Alterman A, O'Brien C, McLellan AT, August D, Snider E, Droba M, Cornish J, Hall C, Raphaelson A, Schrade F (1994). Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. *Journal of Nervous and Mental Disease*, 182, 157–163.

Alterman AI, Randall M, McLellan AT (2000). Comparison of outcomes by gender and for fee-for-service versus managed care: a study of nine community programs. *Journal of Substance Abuse Treatment*, 19, 127–134.

Altice FL, Bruce RD, Walton MR, Buitrago MI (2005). Adherence to hepatitis B virus vaccination at syringe exchange sites. *Journal of Urban Health*, 82, 151–161.

Anglin MD, Brecht M, Maddahian E (1989). Pre-treatment characteristics and treatment performance of legally coerced versus voluntary methadone maintenance admissions. *Criminology*, 27, 537–557.

ASAM (2001). ASAM Placement Criteria for the Treatment of Substance-related Disorders. Chevy Chase, Md.: ASAM.

Avants S, Margolin A, Kosten T, Cooney N (1995). Differences between responders and non-responders to cocaine cues in the laboratory. *Addictive Behaviors*, 20, 215–224.

Bailey SL, Huo D, Garfein RS, Ouellet LJ (2003). The use of needle exchange by young injection drug users. *Journal of Acquired Immune Deficiency Syndromes*, 34, 67–70.

Baker A, Boggs T, Lewin T (2001). Randomised controlled trial of brief cognitive-behavioural interventions among regular users of amphetamine. *Addiction*, 96, 1279–1287.

Baker A, Lee N, Claire M, Grant T, Pohlman S, Saunders J, Kay-Lambkin F, Constable P, Jenner L, Carr V (2005). Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. *Addiction*, 100, 367–378.

Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M (2002). Evaluation of a motivational interview for substance use within psychiatric inpatient services. *Addiction*, 97, 1329–1337.

Ball J, Ross A (1991). The Effectiveness of Methadone Maintenance Treatment. New York: Springer Verlag.

Barber J, Crits-Christoph P, Luborsky L (1996). Effects of therapist adherence and competence on patient outcome in brief dynamic therapy. *Journal of Consulting and Clinical Psychology*, 64, 619–622.

Barrau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemain B, San Marco J (2001). Comparison of methadone and high dosage buprenorphine users in French care centres. *Addiction*, 96, 1433–1441.

Battersby M, Farrell M, Gossop M, Robson P, Strang J (1992). "Horse trading": prescribing injectable opiates to opiate addicts. A descriptive study. *Drug and Alcohol Review*, 11, 35–42.

Battjes RJ, Gordon MS, O'Grady KE, Kinlock TW, Katz EC, Sears EA (2004). Evaluation of a group-based substance abuse treatment program for adolescents. *Journal of Substance Abuse Treatment*, 27, 123–134.

Bearn J, Gossop M, Strang J (1998). Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for inpatient detoxification. *Drug and Alcohol Dependence*, 50, 227–232.

Bearn J, Gossop M, Strang J (1999). Rapid opiate detoxification treatments. *Drug and Alcohol Review*, 18, 75–81.

Belenko S (1979). Alcohol abuse by heroin addicts: review of research findings and issues. *International Journal of the Addictions*, 14, 965–975.

Belenko S (2002). Drug courts. In: Leukefeld C, Tims F, Farabee D, eds. *Treatment of Drug Offenders: Policies and Issues*. New York: Springer.

Belenko S, Peugh J (2005). Estimating drug treatment needs among state prison inmates. *Drug and Alcohol Dependence*, 77, 269–281.

Bell J, Caplehorn JRM, McNeil DR (1994). The effect of intake procedures on performance in methadone maintenance. *Addiction*, 89, 463–471.

Bennett G, Rigby K (1990). Psychological change during residence in a rehabilitation centre for female drug misusers. Part I. Drug misusers. *Drug and Alcohol Dependence*, 27, 149–157.

Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R (2005). Brief motivational intervention at a clinic visit reduces cocaine and heroin use. *Drug Alcohol Dependence*, 77, 49–59.

Best D, Harris J, Gossop M, Manning V, Man LH, Marshall J, Bearn J, Strang J (2001). Are the Twelve Steps more acceptable to drug users than to drinkers? A comparison of experiences of and attitudes to Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) among 200 substance misusers attending inpatient detoxification. *European Addiction Research*, 7, 69–77.

Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J (1999). Accuracy of perceptions of hepatitis B and C status: Cross sectional investigation of opiate addicts in treatment. *British Medical Journal*, 319, 290–291.

Best D, Noble A, Ridge G, Gossop M, Farrell M, Strang J (2002). The relative impact of waiting time and treatment admission on drug and alcohol use. *Addiction Biology*, 7, 67–74.

Birch S, Hesselink JK, Jonkman FA, Hekker TA, Bos A (2004). Clinical research on acupuncture. Part 1. What have reviews of the efficacy and safety of acupuncture told us so far? *Journal of Alternative and Complementary Medicine*, 10: 468–480.

Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR (2000). The effect of syringe exchange use on high-risk injection drug users: a cohort study. *AIDS*, 14, 605–611.

Bradley B, Phillips G, Green L, Gossop M (1989). Circumstances surrounding the initial lapse to opiate use following detoxification. *British Journal of Psychiatry*, 154, 354–359.

Brown B, Kinlock T, Nurco D (2001). Self-help initiatives to reduce the risk of relapse. In: Tims F, Leukefeld C, Platt J, eds. *Relapse and Recovery in Addictions*. New Haven: Yale University Press.

Brown TG, Seraganian P, Tremblay J, Annis H (2002). Process and outcome changes with relapse prevention versus Twelve-Step aftercare programs for substance abusers. *Addiction*, 97, 677–689.

Budney AJ, Higgins ST, Radonovich KJ, Novy PL (2000). Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. *Journal of Consulting and Clinical Psychology*, 68, 1051–1061.

Bullock M, Kiresuk T, Pheley A, Culliton P, Lenz S (1999). Auricular acupuncture in the treatment of cocaine abuse: a study of efficacy and dosing. *Journal of Substance Abuse Treatment*, 16, 31–38.

Burke B, Arkowitz H, Menchola M (2003). The efficacy of : a meta analysis of controlled clinical trials. *Journal of Consulting and Clinical Psychology*, 71, 843–861.

Butzin CA, Martin SS, Inciardi JA (2002). Evaluating component effects of a prison-based treatment continuum. *Journal of Substance Abuse Treatment*, 22, 63–69.

Capelhorn J, Dalton M, Cluff M, Petrenas A (1994). Retention in methadone maintenance and heroin addicts' risk of death. *Addiction*, 82, 203–209.

Carnwath T and Hardman J (1998). Randomised double-blind comparison of lofexidine and clonidine in the outpatient treatment of opiate withdrawal. *Drug and Alcohol Dependence*, 50, 251–254.

Carroll JF, Sobel BS (1986). Integrating mental health personnel and practices into a therapeutic community. In: De Leon G, Ziegenfuss JT, eds. *Therapeutic Communities for Addictions: Readings in Theory, Research and Practice*. Springfield, IL: Charles C. Thomas, s. 209–226.

Carroll KM (1996). Relapse prevention as a psychosocial treatment approach: A review of controlled clinical trials. *Journal of Consulting and Clinical Psychology (Washington, DC)*, 4, 46–54.

Carroll KM (1997). Enhancing retention in clinical trials of psychosocial treatments: practical strategies. In: *Beyond the Therapeutic Alliance: Keeping the Drug-Dependent Individual in Treatment*. Rockville, MD. NIDA Research Monograph 165.

Carroll KM, Libby B, Sheehan J, Hyland N (2001). to enhance treatment initiation in substance abusers: an effectiveness study. *American Journal on Addictions*, 10, 335–339.

Carroll KM, Nich C, Rounsaville BJ (1995). Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. *Journal of Nervous and Mental Disease*, 183, 251–259.

Carroll, KM, Rounsaville BJ, Gawin F H (1991). A comparative trial of psychotherapies for ambulatory cocaine abusers: Relapse prevention and interpersonal psychotherapy. *American Journal of Drug and Alcohol Abuse*, 17, 229–247.

Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F (1994). One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. *Archives of General Psychiatry*, 51, 989–997.

Chan M, Sorensen J, Guydish J, Tajima B, Acampora A (1997). Client satisfaction with drug abuse day treatment versus residential care. *Journal of Drug Issues*, 27, 367–377.

Chatham, LR, Rowan-Szal GA, Joe GW, Simpson DD (1997). Heavy drinking, alcohol dependent versus non-dependent methadone maintenance clients: A follow-up study. *Addictive Behaviours*, 22, 69–80.

Childress AR, McLellan A, Ehrman R, O'Brien C (1988). Classically conditioned responses in opioid and cocaine dependence: a role in relapse? In: Ray B, ed. *Learning Factors in Substance Abuse*. Washington. NIDA Monogr. 84, s. 25–43.

Childress AR, McLellan A, O'Brien C (1984). Measurement and extinction of conditioned withdrawal-like responses in opiate dependent patients. In: Harris L, ed. *Problems of Drug Dependence*. Washington. NIDA Monogr. 49, s. 212–219.

Childress A, McLellan A, O'Brien C (1986). Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. *British Journal of Addiction*, 81, 655–660.

Christo G, Sutton S (1994). Anxiety and self-esteem as a function of abstinence time among recovering addicts attending Narcotics Anonymous. *British Journal of Clinical Psychology*, 33, 198–200.

Christo G, Franey C (1995). Drug users' spiritual beliefs, locus of control and the disease concepts in relation to NA attendance and six-month outcomes. *Alcohol Dependence*, 38, 51–56.

Chutuape M, Silverman K, Stitzer M (1998). Survey assessment of methadone treatment services as reinforcers. *American Journal of Drug and Alcohol Abuse*, 24, 1–16.

Cole SG, James LR (1975). A revised treatment typology based on the DARP. *American Journal of Drug and Alcohol Abuse*, 2, 37–49.

Collins E, Kleber H, Whittington R, Heitler N (2005). Anaesthesiaassisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomised trial. *Journal of the American Medical Association*, 294, 903–913.

Conklin C, Tiffany S (2002). Applying extinction research and theory to cue exposure addiction treatments. *Addiction*, 97, 155–167.

Cook C (1988). The Minnesota Model in the management of drug and alcohol dependency: miracle, method or myth? Part II. Evidence and conclusions. *British Journal of Addiction*, 83, 735–748.

Cooper JR, Altman F, Brown B and Czechowicz D (1983). Research on the treatment of Narcotic addiction: state of the art. *NIDA Treatment Research Monograph Series*: Rockville: US Department of Health and Human Services.

Copeland J, Swift W, Roffman R, Stephens R (2001). A randomised controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. *Journal of Substance Abuse Treatment*, 21, 55–64.

Crape BL, Latkin CA, Laris AS, Knowlton AR (2002). The effects of sponsorship in Twelve-Step treatment of injection drug users. *Drug and Alcohol Dependence*, 65, 291–301.

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, Muenz L, Thase ME, Weiss RD, Gastfriend DR, Woody G, Barber JP, Butler SF, Daley D, Bishop S, Najavits LM, Lis J, Mercer D, Griffin

ML, Moras K, Beck AT (1997). The National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Rationale and methods. *Archives of General Psychiatry*, 54, 721–726.

Crowley T, Wagner J, Zerbe G, MacDonald M (1985). Naltrexoneinduced dysphoria in former opioid addicts. *American Journal of Psychiatry*, 142, 1081–1084.

Cummings N, Gordon J, Marlatt G (1980). Relapse: strategies of prevention and prediction. In: Miller WR, ed. *The Addictive Behaviors*. Oxford: Pergamon.

Daley D, Salloum I, Zuckoff A, Kirisci L, Thase M (1998). Increasing treatment adherence among outpatients with cocaine dependence: results of a pilot study. *American Journal of Psychiatry*, 155, 1611–1613.

Dansereau DF, Evans SH, Czuchry M, Sia TL (2003). Readiness and mandated treatment: development and application of a functional model. *Offender Substance Abuse Report*, 31, 13–16.

Darke S, Zador D (1996). Fatal heroin 'overdose': a review. *Addiction*, 91, 1765–1772.

D'Aunno T, Vaughn T (1995). An organisational analysis of service patterns in outpatient drug abuse treatment units. *Journal of Substance Abuse*, 7, 27–42.

Davis TM, Carpenter KM, Malte CA, Carney M, Chambers S, Saxon AJ (2002). Women in addictions treatment: comparing VA and community samples. *Journal of Substance Abuse Treatment*, 23, 41–48.

Dawe S, Griffiths P, Gossop M, Strang J (1991). Should opiate addicts be involved in controlling their own detoxification? A comparison of fixed versus negotiable schedules. *British Journal of Addictions*, 86, 977–982.

Dawe S, Powell J, Richards D, Gossop M, Marks I, Strang J, Gray J (1993). Does post-withdrawal cue exposure improve outcome in opiate addiction? A controlled trial. *Addiction*, 88, 1233–1245.

De Leon G (1989). Alcohol: the hidden drug among substance abusers. *British Journal of Addiction*, 84, 837–840.

De Leon G (2000). *The Therapeutic Community: Theory, Model and Method*. New York: Springer.

De Leon G, Jainchill N, Wexler H (1982). Success and improvement rates five years after treatment in a therapeutic community. *International Journal of Addictions*, 17, 703–747.

De Leon G, Rosenthal MS (1979). Therapeutic communities. In: DuPont R, Goldstein A, O'Donnell J, eds. *Handbook on Drug Abuse*. Rockville, MD: National Institute on Drug Abuse, s. 39–48.

De Leon G, Staines G, Perlis T, Sacks S, McKendrick K, Hilton R, Brady R (1995). Therapeutic community methods in methadone maintenance (Passages): an open clinical trial. *Drug and Alcohol Dependence*, 37, 45–57.

Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, Liddle H, Titus JC, Kaminer Y, Webb C, Hamilton N, Funk R (2004). The Cannabis Youth Treatment (CYT) Study: main findings from two randomised trials. *Journal of Substance Abuse Treatment*, 27, 197–213.

Dettmer K, Saunders B, Strang J (2001). Take-home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. *British Medical Journal*, 322, 895–896.

Dolan K, Rutter S, Wodak AD (2003). Prison-based syringe exchange programmes: a review of international research and development. *Addiction*, 98, 153–158.

Dole V, Joseph H (1978). Long-term outcome of patients treated with methadone maintenance. *Annals of the New York Academy of Sciences*, 311, 181–189.

Drummond DC, Tiffany S, Glautier S, Remington B (1995). Cue exposure in understanding and treating addictive behaviour. In: Drummond DC, Tiffany S, Glautier S, Remington B, eds. *Addictive Behaviours: Cue Exposure Theory and Practice*. London: Wiley.

Dunn C, DeRoo L, Rivara F (2001). The use of brief interventions adapted from across behavioural domains: a systematic review. *Addiction*, 96, 1725–1742.

DuPont R, McGovern J (1994). *A bridge to recovery: an Introduction to Twelve-Step Programs*. Washington: American Psychiatric Association.

Durante AJ, Hart GJ, Brady AR, Madden PB, Noone A (1995). The Health of the Nation target on syringe sharing: a role for routine surveillance in assessing progress and targeting interventions. *Addiction*, 90, 1389–1396.

Egelko S, Galanter M, Dermatis H, Jurewicz E, Jamison A, Dingle S, De Leon G (2002). Improved psychological status in a modified therapeutic community for homeless MICA men. *Journal of Addictive Diseases*, 21, 75–92.

Egg R, Pearson FS, Cleland CM, Lipton DS (2000). Evaluations of correctional treatment programmes in Germany: a review and meta analysis. *Substance Use and Misuse*, 35, 1967–2009.

Emrick CD (1999). Alcoholics Anonymous and other Twelve-Step groups. In: Galanter M, Kleber HD, eds. *The American Psychiatric Press Textbook of Substance Abuse Treatment*. 2nd ed. Washington, D.C.: American Psychiatric Press, Inc., s. 403–412.

Etheridge RM, Craddock SG, Duntzman GH, Hubbard RL (1995). Treatment services in two national studies of communitybased drug abuse treatment programs. *Journal of Substance Abuse Treatment*, 7, 9–26.

Treating drug misuse problems: evidence of effectiveness

Etheridge R, Craddock S, Hubbard R, Rounds-Bryant J (1999). The relationship of counselling and self-help participation to patient outcomes in DATOS. *Drug and Alcohol Dependence*, 57, 99–112.

Etheridge R, Hubbard R, Anderson J, Craddock G, Flynn P (1997). Treatment structure and program services in the Drug Abuse Treatment Outcome Study (DATOS). *Psychology of Addictive Behaviors*, 11, 244–260.

Farrell M, Howes S, Taylor C, Lewis G, Jenkins R, Bebbington P, Jarvis M, Brugha T, Gill B, Meltzer H (1998). Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. *Addictive Behaviors*, 23, 909–918.

Farrell M, Neeleman J, Griffiths P, Strang J (1996). Suicide and overdose among opiate addicts. *Addiction*, 91: 321–323.

Festinger DS, RJ Lamb MR Kountz, KC Kirby, Marlowe D (1995). Pre-treatment dropout as a function of treatment delay and client variables, *Addictive Behaviors*, 20, 111–115.

Fhima A, Henrion R, Lowenstein W, Charpak Y (2001). Two-year follow-up of an opioid user cohort treated with high-dose buprenorphine (Subutex). *Annales de Medecine Interne*, 152, 2636.

Finney JW, Ouimette PC, Humphreys K, Moos RH (2001). A comparative, process effectiveness evaluation of VA substance abuse treatment. *Recent Developments in Alcoholism*, 15, 373–391.

Fiorentine R (1999). After drug treatment: Are Twelve-Step programs effective in maintaining abstinence? *American Journal of Alcohol Abuse*, 25: 93–116.

Fiorentine R (2001). Counselling frequency and the effectiveness of outpatient drug treatment: revisiting the conclusion that "more is better" *American Journal of Drug and Alcohol Abuse*, 27, 617–631.

Fiorentine R, Anglin D (1996). More is better: counselling participation and the effectiveness of outpatient drug treatment. *Journal of Substance Abuse Treatment*, 13, 341–348.

Fiorentine R and Anglin MD (1997). Does increasing the opportunity for counselling increase the effectiveness of outpatient drug treatment? *American Journal of Drug and Alcohol Abuse*, 23, 369–382.

Fiorentine R, Hillhouse M (2000). Drug treatment and Twelve-Step program participation: the additive effects of integrated recovery activities. *Journal of Substance Abuse Treatment*, 18, 65–74.

Flemming P (1998). Prescribing amphetamine to amphetamine users as a harm-reduction measure. *International Journal of Drug Policy*, 9, 339–344.

Flemming P, Roberts D (1994). Is the prescription of amphetamine justified as a harm reduction measure? *Journal of the Royal Society of Health*, 127–131.

Fountain J, Strang J, Gossop M, Farrell M, Griffiths P (2000). Diversion of drugs prescribed to drug users in treatment: analysis of the UK market and new data from London. *Addiction*, 95, 393–406.

Friedmann PD, Hendrickson JC, Gerstein DR, Zhang Z (2004). The effect of matching comprehensive services to patients' needs on drug use improvement in addiction treatment. *Addiction*, 99, 962–972.

Friedman S, Jose B, DesJarlais D, Neagus A (1995). Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium. *American Journal of Epidemiology*, 142, 864–874.

Frischer M, Bloor M, Goldberg D, Clark J, Green S, McKeganey N (1993). Mortality among injecting drug users: a critical reappraisal. *Journal of Epidemiology and Community Health*, 47, 59–63.

Gardner R, Connell PH (1972). Amphetamine and other nonopioid drug users attending a special drug dependence clinic. *British Medical Journal*, 2, 322-325.

Garfein R, Vlahov D, Galai N, Doherty M, Nelson K (1996). Viral infections in short term injecting drug users: the prevalence of hepatitis C, hepatitis B, Human Immunodeficiency and Human T-Lymphotropic viruses. *American Journal of Public Health*, 86, 655-661.

Ghodse AH (1978). The attitudes of casualty staff and ambulance personnel towards patients who take drug overdoses. *Social Science and Medicine*, 12, 341-346.

Gibson DR, Brand R, Anderson K, Kahn JG, Perales D, Guydish J (2002). Two- to six-fold decreased odds of HIV risk behavior associated with use of syringe exchange. *Journal of Acquired Immune Deficiency Syndromes*, 31, 237-242.

Gibson DR, Flynn NM, McCarthy JJ (1999). Effectiveness of methadone treatment in reducing HIV risk behaviour and HIV seroconversion among injecting drug users. *AIDS*, 13, 1807-1818.

Gibson DR, Flynn NM, Perales D (2001). Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. *AIDS*, 27, 1329-1341.

Gossop M (1988). Clonidine and the treatment of the opiate withdrawal syndrome. *Drug and Alcohol Dependence*, 21, 253-259.

Gossop M (1989a). *Relapse and Addictive Behaviour*. London: Routledge.

Gossop M (1995). The treatment mapping survey; a descriptive study of drug and alcohol treatment responses in 23 countries. *Drug and Alcohol Dependence*, 39, 7-14.

Gossop M, Bradley B, Strang J, Connell P (1984). The clinical effectiveness of electrostimulation versus oral methadone in managing opiate withdrawal. *British Journal of Psychiatry*, 144, 203-208.

Gossop M, Green L, Phillips G, Bradley B (1989a). Lapse, relapse and survival among opiate addicts after treatment: a prospective follow-up study. *British Journal of Psychiatry*, 154, 348-353.

Gossop M, Green L, Phillips G, Bradley B (1990). Factors predicting outcome among opiate addicts after treatment. *British Journal of Clinical Psychology*, 29, 209-216.

Gossop M, Grant M (1991). A study of the content and structure of heroin treatment programmes using methadone in six countries. *British Journal of Addiction*, 86, 1151-1160.

Gossop M, Griffiths P, Bradley B, Strang J (1989b). Opiate withdrawal symptoms in response to ten-day and 21-day methadone withdrawal programmes. *British Journal of Psychiatry*, 154, 360-363.

Gossop M, Griffiths P, Powis B, Williamson S, Strang J (1996). Frequency of non-fatal heroin overdose: survey of heroin users recruited in non-clinical settings. *British Medical Journal*, 313, 402.

Gossop M, Griffiths P, Powis B, Williamson S, Fountain J, Strang J (1997). Continuing drug risk behaviour: shared use of injecting paraphernalia among London heroin injectors. *AIDS CARE*, 9, 651-660.

Gossop M, Johns A, Green L (1986). Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. *British Medical Journal*, 293, 103-104.

Gossop M, Manning V, Ridge G (2006). Concurrent use of alcohol and cocaine: differences in patterns of use and problems among users of crack cocaine and powder cocaine. *Alcohol and Alcoholism*, 41, 121-125.

Gossop M, Marsden J, Stewart D (1998). NTORS at one year: changes in substance use, health and criminal behaviour one year after intake. London: Department of Health.

Gossop M, Marsden J, Stewart D, Lehmann P, Strang J (1999). Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. *British Journal of General Practice*, 49, 31-34.

Gossop M, Marsden J, Stewart D, Kidd T (2002). Changes in use of crack cocaine after drug misuse treatment: 4-5 year follow-up results from the National Treatment Outcome Research Study (NTORS). *Drug and Alcohol Dependence*, 66, 21-28.

Gossop M, Marsden J, Stewart D, Kidd T (2003). The National Treatment Outcome Research Study (NTORS): 4-5 year followup results. *Addiction*, 98, 291-303.

Gossop M, Marsden J, Stewart D, Lehmann P, Edwards C, Wilson A, Segar G (1998). Substance use, health and social problems of clients at 54 drug treatment agencies: intake data from the National Treatment Outcome Research Study (NTORS). *British Journal of Psychiatry*, 173, 166-171.

Gossop M, Marsden J, Stewart D, Rolfe A (1999). Treatment retention and one-year outcomes for residential programmes in England. *Drug and Alcohol Dependence*, 57, 89–98.

Gossop M, Marsden J, Stewart D, Rolfe A (2000a). Patterns of improvement after methadone treatment: one-year follow-up results from the National Treatment Outcome Research Study (NTORS). *Drug and Alcohol Dependence*, 60, 275–286.

Gossop M, Marsden J, Stewart D, Rolfe, A (2000b). Patterns of drinking and drinking outcomes among drug misusers: one-year follow-up results. *Journal of Substance Abuse Treatment*, 19, 45–50.

Gossop M, Marsden J, Stewart D, Treacy S (2001). Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. *Drug and Alcohol Dependence*, 62, 255–264.

Gossop M, Marsden J, Stewart D, Treacy S (2002). Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. *AIDS Care*, 14, 77–93.

Gossop M, Powis B, Griffiths P, Strang J (1994). Multiple risks for HIV and hepatitis B infection among heroin users. *Drug and Alcohol Review*, 13, 293–300.

Gossop M, Stewart D, Browne N, Marsden J (2002). Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. *Addiction*, 97, 1259–1267.

Gossop M, Stewart D, Marsden J (2003). Treatment process components and heroin use outcome among methadone patients. *Drug and Alcohol Dependence*, 71, 93–102.

Gossop M, Stewart D, Marsden J (2006). Effectiveness of drug and alcohol counselling during methadone treatment: content, frequency, and duration of counselling, and association with substance use outcomes. *Addiction*, 3, 404–412.

Gossop M, Strang J (1991). A comparison of the withdrawal responses of heroin and methadone addicts during detoxification. *British Journal of Psychiatry*, 158, 697–699.

Gossop M, Strang J, Connell P (1982). The response of outpatient opiate addicts to the provision of a temporary increase in their prescribed drugs. *British Journal of Psychiatry*, 141, 338–343.

Gossop M, Trakada K, Stewart D, Witton J (2005). Reductions in criminal convictions after addiction treatment: five-year follow-up. *Drug and Alcohol Dependence*, 79, 295–302.

Gottheil E, Thornton C, Weinstein SP (2002). Effectiveness of high versus low structure individual counselling for substance abuse, *The American Journal on Addictions*, 11, 279–290.

Grabowski J, O'Brien C, Greenstein R, Ternes J, Long M, Steinberg Donato S (1979). Effects of contingent payment on compliance with a naltrexone regimen. *American Journal of Drug and Alcohol Abuse*, 6, 355–365.

Greenstein RA, O'Brien C P, McLellan A T, Woody G E, Grabowski J, Long M, Coyle Perkins G, Vittor A (1981). Naltrexone: a short term treatment for opiate dependence. *American Journal of Drug and Alcohol Abuse*, 8, 291–300.

Grella C, Hser Y, Joshi V, Anglin D (1999). Patient histories, retention, and outcome models for younger and older adults in DATOS. *Drug and Alcohol Dependence*, 57, 151–166.

Griffith J, Rowan Szal G, Roark R, Simpson D (2000). Contingency management in outpatient methadone treatment: a meta analysis. *Drug and Alcohol Dependence*, 58, 55–66.

Hagan H, Jarlais D, Friedman S, Purchase D, Alter M (1995). Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. *American Journal of Public Health*, 85, 1490–1491.

Hahn JA, Vranizian KM, Moss AR (1997). Who uses needle exchange? A study of injection drug users in treatment in San Francisco, 1989–1990. *Journal of Acquired Immune Deficiency Syndromes*, 15, 157–164.

Hall S, Bass A, Hargreaves W, Loeb P (1979). Contingency management and information feedback in outpatient heroin detoxification. *Behaviour Therapy*, 10, 443–451.

Hall W (1999). Reducing the toll of opioid overdose deaths in Australia. *Drug and Alcohol Review*, 18, 213–220.

Hall W, Farrell M (1997). Comorbidity of mental disorders with substance misuse. *British Journal of Psychiatry*, 171, 4–5.

Hartel DM, Schoenbaum EE (1998). Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. *Public Health Reports*, 113, 107–115.

Hartnoll R, Mitcheson M, Battersby A, Brown G, Ellis M, Flemming P, Hedley N (1980). Evaluation of heroin maintenance in controlled trial. *Archives of General Psychiatry*, 37, 877–884.

Havassy B, Wasserman D, Hall S (1995). Social relationships and abstinence from cocaine in an American treatment sample. *Addiction*, 90, 699–710.

Heather N (1998). Using brief opportunities for change in medical settings. In: Miller W, Heather N, eds. *Treating Addictive Behaviors*. New York: Plenum Press.

Heather N (2002). Effectiveness of brief interventions proved beyond reasonable doubt, *Addiction*, 97, 293–294.

Heather N, Bradley B (1990). Cue exposure as a practical treatment for addictive disorders: why are we waiting? *Addictive Behaviors*, 15, 335–337.

Heather N, Stallard A (1989). Does the Marlatt model underestimate the importance of conditioned craving in the relapse process? In: Gossop M, ed. *Relapse and Addictive Behaviour*. London: Routledge.

Heinrich C, Lynn L (2002). Improving the organisation, management, and outcomes of substance abuse treatment programs. *American Journal of Drug and Alcohol Abuse*, 28, 601–622.

Hettema J, Steele J, Miller W (2005). ?????????????? *Annual Review of Clinical Psychology*, 1, 91–111.

Higgins ST, Budney AJ, Bickel WK, Badger GJ (1993). Participation of significant others in outpatient behavioral treatment predicts greater cocaine abstinence. *American Journal of Drug and Alcohol Abuse*, 20, 47–56.

Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ (1994). Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. *Archives of General Psychiatry*, 51, 568–576.

Higgins S, Delaney D, Budney A, Bickel W, Hughes J, Foerg F, Fenwick J (1991). A behavioral approach to achieving initial cocaine abstinence. *American Journal of Psychiatry*, 148, 1218.

Hiller ML, Knight K, Simpson DD (1999). Prison-based substance abuse treatment, residential aftercare and recidivism. *Addiction*, 94, 833–842.

Hillhouse M, Fiorentine R (2001). Twelve-Step program participation and effectiveness: do gender and ethnic differences exist? *Journal of Drug Issues*, 31, 767–780.

Hoffman JA, Caudill BD, Koman JJ, Luckey JW, Flynn PM, Hubbard RL (1994). Comparative cocaine abuse treatment strategies: enhancing client retention and treatment exposure. *Journal of Addictive Diseases*, 13, 115–128.

Hollister L, Johnson K, Boukhabza D, Gillespie H (1981). Aversive effects of naltrexone in subjects not dependent on opiates. *Drug and Alcohol Dependence*, 8, 37–41.

Horgan C (1997). Need and access to drug abuse treatment. In: Egerton JA, Fox DM, Leshner AI, eds. *Treating Drug Abusers Effectively*. Oxford: Blackwell.

Hough M, Clancy A, McSweeney T, Turnbull P (2003). The impact of drug treatment and testing orders on offending: two year reconviction results. *Findings* 184. London: Home Office.

Hser YI, Teruya C, Evans E, Longshore D, Grella C, Farabee D (2003b). Treating drug abusing offenders: initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes. *Evaluation Review*, 27, 479–505.

Hser YI, Evans E, Huang YC (2005). Treatment outcomes among women and men methamphetamine abusers in California. *Journal of Substance Abuse and Treatment*, 28, 77–85.

Hser YI, Huang D, Teruya C, Douglas Anglin M (2003). Gender comparisons of drug abuse treatment outcomes and predictors. *Drug Alcohol Dependence*, 72, 255–264.

Hser ML, Polinsky M, Maglione MD, Anglin (1999). Matching clients' need with drug treatment services, *Journal of Substance Abuse Treatment*, 16, 299–305.

Hubbard RL, Cavanaugh ER, Craddock SG, Rachel JV (1985). Characteristics, behaviors, and outcomes for youth in the TOPS: Treatment services for adolescent substance abusers In: Friedman AS,

Beschner GM, eds. *Treatment Services for Adolescent Substance Abusers*. Rockville, MD: National Institute on Drug Abuse, s. 49–65.

Hubbard RL, Craddock SG, Flynn P, Anderson J, Etheridge R (1997). Overview of one-year outcomes in the Drug Abuse Treatment Outcome Study (DATOS). *Psychology of Addictive Behaviors*, 11, 279–293.

Hubbard R L, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzberg HM (1989). *Drug Abuse Treatment: A National Study of Effectiveness*. London: Chapel Hill.

Hulse GK, English DR, Milne E, Holman CDJ (1999). The quantification of mortality resulting from the regular use of illicit opiates. *Addiction*, 94, 221–229.

Humphreys K (2004). *Circles of recovery: self-help organisations for addictions*. Cambridge: Cambridge University Press.

Humphreys K, Dearmin P, Moos R, Finney J (1999). A comparative evaluation of substance abuse treatment: V. Treatment can enhance the effectiveness of self-help groups. *Alcoholism: Clinical and Experimental Research*, 23, 558–563.

Hunt DE, Strug DI, Goldsmith DS, Lipton DS, Spunt B, Robertson K and Truitt L (1986). Alcohol use and abuse: heavy drinking among methadone clients. *American Journal of Drug and Alcohol Abuse*, 12: 147–164.

Hunt WA, Barnett LW, Branch L G (1971). Relapse rates in addiction programs. *Journal of Clinical Psychology*, 27, 455–456.

Hurley S, Jolley D, Kaldor J (1997). Effectiveness of needle exchange programmes for prevention of HIV infection. *Lancet*, 349, 1797–1800.

Iguchi M, Lamb R, Belding M, Platt J, Husband S, Morral A (1996). Contingent reinforcement of group participation versus abstinence in a methadone maintenance program. *Journal of Consulting and Clinical Psychology*, 4, 315–321.

Iguchi MY, Stitzer ML (1991). Predictors of opiate drug abuse during a 90-day methadone detoxification. *American Journal of Drug and Alcohol Abuse*, 17, 279–229.

Iguchi M, Stitzer M, Bigelow G, Liebson I (1988). Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. *Drug and Alcohol Dependence*, 22, 1–7.

Institute of Medicine (1990). *Treating Drug Problems*. Vol. 1. Gerstein D, Harwood H, eds. Washington, DC: National Academy Press.

Joe G, Friend H (1989). Treatment process factors and satisfaction with drug abuse treatment. *Psychology of Addictive Behaviors*, 3, 53–64.

Joe GW, Simpson DD (1975). Retention in treatment of drug users: 1971–1972 DARP admissions. *American Journal of Drug and Alcohol Abuse*, 2, 63–71.

Joe G, Simpson D, Broome K (1999). Retention and patient engagement models for different treatment modalities in DATOS. *Drug and Alcohol Dependence*, 57, 13–125.

Joe GW, Simpson DD, Broome KM (1998). Effects of readiness for drug abuse treatment on client retention and assessment of process. *Addiction*, 93, 1177–1190.

Joe GW, Simpson DD, Hubbard RL (1991). Treatment predictors of tenure in methadone maintenance. *Journal of Substance Abuse*, 3, 73–84.

Johnsen E, Herringer L (1993). A note on the utilisation of common support activities and relapse following substance abuse treatment. *Journal of Psychology*, 127, 73–78.

Johnson R, Chutuape M, Strain E, Walsh S, Stitzer M, Bigelow G (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *New England Journal of Medicine*, 343, 1290–1297.

Jones H, Silverman K, Stitzer M, Svikis D (2001). The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone maintained pregnant women. *Drug and Alcohol Dependence*, 61, 297–306.

Kessler R, McGonagle K, Zhao S (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Study. *Archives of General Psychiatry*, 51, 8–19.

Kidorf M, Stitzer M (1993). Descriptive analysis of cocaine use of methadone patients. *Drug and Alcohol Dependence*, 32, 267.

Kidorf, M, Stitzer ML, Brooner, RK, Goldberg J (1994). Contingent methadone take home doses reinforce adjunct therapy attendance of methadone maintenance patients. *Drug and Alcohol Dependence*, 36, 221–226.

Kleber H, Kosten T, Gaspari J, Topazian M (1985). Non-tolerance to the opioid antagonism of naltrexone. *Biological Psychiatry*, 20, 66–72.

Klein C, di Menza S, Arfken C, Schuster CR (2002). Interaction effects of treatment setting and client characteristics on retention and completion. *Journal of Psychoactive Drugs*, 34, 39–50.

Kleinman P, Goldsmith D, Friedman S, Hopkins W, DesJarlais D (1990). Knowledge about and behaviours affecting the spread of AIDS: a street survey of intravenous drug users and their associates in New York. *International Journal of the Addictions*, 24, 345–361.

Knight K, Simpson DD, Hiller M (1999). Three-year reincarceration outcomes for in-prison therapeutic community treatment in Texas. *Prison Journal*, 79, 337–351.

Kosten TR, Morgan C, Kleber H (1992). Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. In: Blaine J, ed. *NIDA Research Monograph: Buprenorphine, An Alternative Treatment for Opioid Dependence* Rockville, MD, s. 101–119.

Krantz M, Mehler P (2004). Treating opioid dependence: growing implications for primary care. *Archives of Internal Medicine*, 164, 277–288.

Kreek MJ (1981). Medical management of methadone maintained patients. In: *Substance Abuse: Clinical Problems and Perspectives*. Lowinson J, Ruiz P, eds. Baltimore: Williams and Wilkins.

Kreek MJ (2000). Methadone related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. *Annals of the New York Academy of Sciences*, 909, 186–216.

Kreek MJ, Vocci F (2002). History and current status of opioid maintenance treatments. *Journal of Substance Abuse Treatment*, 23, 93–105.

Ksobiech K (2003). A meta analysis of needle sharing, lending, and borrowing behaviors of needle exchange program attenders. *AIDS Education and Prevention*, 15, 257–268.

Kuo I, Brady J, Butler C, Schwartz R, Brooner R, Vlahov D, Strathdee SA (2003). Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance. *Journal of Substance Abuse Treatment*, 24, 67–74.

Lehman WER, Simpson DD (1990). Alcohol use. In: Simpson DD, Sells SB, eds. *Opioid Addiction and Treatment: a 12-year follow-up*. Melbourne, FL: Kreiger, s. 177–192.

Leshner A (1997). Introduction to the special issue: the National Institute on Drug Abuse Drug Abuse Treatment Outcome Study (DATOS). *Psychology of Addictive Behaviors*, 11, 211–215.

Liddle HA, Dakof GA, Parker K, Diamond GS, Barrett K, Tejeda M (2001). Multidimensional family therapy for adolescent drug abuse: results of a randomised clinical trial. *American Journal of Drug and Alcohol Abuse*, 27, 651–688.

Lincourt P, Kuettel T, Bombardier C (2002). in a group setting with mandated clients: a pilot study. *Addictive Behaviors*, 27, 381–391.

Ling W, Wesson D (1984). Naltrexone treatment for addicted healthcare professionals: a collaborative private practice experience. *Journal of Clinical Psychiatry*, 49, 46–48.

Lipton D, Maranda M (1983). Detoxification from heroin dependency: an overview of method and effectiveness. In: Stimmel B, ed. *Evaluation of Drug Treatment Programmes*. New York: Haworth, s. 31–55.

Litwin AH, Soloway I, Gourevitch MN (2005). Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. *Clinical Infectious Diseases*, 40, 339–345.

Love J, Gossop M (1985). The processes of referral and disposal within a London drug dependence clinic. *British Journal of Addiction*, 80, 435–440.

McBride AJ, Sullivan G, Blewitt AE and Morgan S (1997). Amphetamine prescribing as a harm reduction measure: a preliminary study. *Addiction Research*, 5, 95–112.

McCambridge J, Strang J (2005). Deterioration over time in effect of in reducing drug consumption and related risk among young people. *Addiction*, 100, 470–478.

McCaughrin WC, Howard DL (1996). Variation in access to outpatient substance abuse treatment: organisational factors and conceptual issues. *Journal of Substance Abuse*, 8, 403–415.

McCusker J, Bigelow C, Vickers-Lahti M, Spotts D, Garfield F, Frost R (1997). Planned duration of residential drug abuse treatment: efficacy versus effectiveness. *Addiction*, 92, 1467–1478.

McCusker J, Vickers Lahti M, Stoddard A, Hindin R, Bigelow C, Zorn M, Garfield F, Frost R, Love C, Lewis B (1995). The effectiveness of alternative planned durations of residential drug abuse treatment. *American Journal of Public Health*, 85, 1426–1429.

McKay J, Alterman A, McLellan AT, Snider E (1994). Treatment goals, continuity of care, and outcome in a day hospital substance abuse rehabilitation program. *American Journal of Psychiatry*, 151, 254–259.

McKay JR, Alterman AI, Rutherford MJ, Cacciola JS, McLellan AT (1999). The relationship of alcohol use to cocaine relapse in cocaine-dependent patients in an aftercare study. *Journal of Studies on Alcohol*, 60, 176–180.

McKay JR, Cacciola JS, McLellan AT, Alterman AI, Wirtz PW (1997). An initial evaluation of the psychosocial dimensions of the American Society of Addiction Medicine criteria for inpatient versus intensive outpatient substance abuse rehabilitation. *Journal of Studies on Alcohol*, 58, 239–252.

McKay JR, Donovan DM, McLellan T, Krupski A, Hansten M, Stark KD, Geary K, Cecere J (2002). Evaluation of full versus partial continuum of care in the treatment of publicly funded substance abusers in Washington State. *American Journal of Drug and Alcohol Abuse*, 28, 307–338.

McLatchie B, Lomp K (1988). Alcoholics Anonymous affiliation and treatment outcome among a clinical sample of problem drinkers. *American Journal of Alcohol Abuse*, 14, 309–324.

McLellan AT, Alterman AI, Metzger DS, Grissom GR, Woody GE, Luborsky L, O'Brien CP (1994). Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. *Journal of Consulting and Clinical Psychology*, 62, 1141–1158.

McLellan AT, Arndt I, Metzger D, Woody G, O'Brien C (1993). The effects of psychosocial services in substance abuse treatment. *Journal of the American Medical Association*, 269, 1953–1959.

McLellan AT, Childress A, Ehrman A, O'Brien C, Pasko S (1986). Extinguishing conditioned responses during opiate dependence treatment: turning laboratory findings into clinical procedures. *Journal of Substance Abuse Treatment*, 3, 33–40.

McLellan AT, Grissom GR, Zanis DA, Randall M, Brill P, O'Brien CP (1997). Problem-service matching in addiction treatment: a prospective study in four programs. *Archives of General Psychiatry*, 54, 730–735.

McLellan AT, Hagan TA, Levine M, Gould F, Meyers K, Bencivengo M and Durell J (1998). Supplemental social services improve outcomes in public addiction treatment. *Addiction*, 93, 1489–1499.

McLellan AT, Luborsky L, Woody G, Druley K, O'Brien C (1983). Predicting response to alcohol and drug abuse treatments: role of psychiatric severity. *Archives of General Psychiatry*, 40, 620–625.

McLellan AT, Wood GE, Metzger DS, McKay J, Alterman AI (1997). Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. In: Egerton JA, Fox DM, Leshner AI, eds. *Treating Drug Abusers Effectively*. Oxford: Blackwell.

McRae AL, Budney AJ, Brady KT (2003). Treatment of marijuana dependence: a review of the literature. *Journal of Substance Abuse Treatment*, 24, 369–376.

Maddux J, Desmond D, Esquivel M (1980). Outpatient methadone withdrawal for heroin dependence. *American Journal of Drug and Alcohol Abuse*, 7, 323–333.

Maggio CA, Presta E, Bracco EF (1985). Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. *Brain Research Bulletin*, 14, 657–661.

Makela K (1993). International comparisons of Alcoholics Anonymous. *Alcohol, Health, and Research World*, 17, 228–234.

Margolin A, Kleber HD, Avants SK, Konefal J, Gawin F, Stark E, Sorensen J, Midkiff E, Wells E, Jackson TR, Bullock M, Culliton PD, Boles S, Vaughan R (2002). Acupuncture for the treatment of cocaine addiction: a randomised controlled trial. *JAMA*, 287, 55–63.

Marijuana Treatment Project Research Group (2004). Brief treatments for cannabis dependence: findings from a randomised multi-site trial. *Journal of Consulting and Clinical Psychology*, 72, 455–466.

Marlatt GA (1985). Relapse prevention: theoretical rationale and overview of the model. In: Marlatt GA, Gordon JR, eds. *Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behavior*. New York: Guilford Press.

Marlatt GA, Gordon JR (1985). *Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behavior*. New York: Guilford Press.

Marrazzi M, Wroblewski J, Kinzie J, Lubie E (1997). High dose naltrexone and liver function safety. *American Journal on Addictions*, 6, 21–29.

Marsch LA (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour and criminality: a meta analysis. *Addiction*, 93, 515–532.

Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M (2000). Psychiatric symptoms amongst clients seeking treatment for drug dependence: intake data from the National Treatment Outcome Research Study. *British Journal of Psychiatry*, 176, 285–289.

Marsh J, D'Aunno T, Smith B (2000). Increasing access and providing social services to improve drug abuse treatment for women with children. *Addiction*, 95, 1237–1247.

Martin D, Garske J, Davis M (2000). Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. *Journal of Consulting and Clinical Psychology*, 68, 438–450.

Martin S, Butzin C, Saum C, Inciardi J (1999). Three-year outcomes of therapeutic community treatment for drug-involved offenders in Delaware: from prison to work release to aftercare. *Prison Journal*, 79, 294–320.

Martin W, Jasinski D, Mansky P (1973). Naltrexone: an antagonist for the treatment of heroin dependence. *Archives of General Psychiatry*, 28, 784–791.

Masson CL, Barnett PG, Sees KL, Delucchi KL, Rosen A, Wong W, Hall SM (2004). Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180day methadone detoxification. *Addiction*, 99, 718–726.

Mattick R, Oiphant D, Ward J, Hall W (1998). The effectiveness of other opioid replacement therapies: LAAM, heroin, buprenorphine, naltrexone and injectable maintenance. In: Ward J, Mattick R, Hall W, eds. *Methadone Maintenance Treatment and Other Replacement Therapies*. Amsterdam: Harwood.

Meichenbaum D, Turk D (1987). *Facilitating Treatment Adherence*. New York: Plenum.

Mello N, Mendelson J, Kuehnle J, Sellers M (1981). Operant analysis of human heroin self-administration and the effects of naltrexone. *Journal of Pharmacology and Experimental Therapeutics*, 216, 45–54.

Messina N, Wish E, Nemes S (2000). Predictors of treatment outcomes in men and women admitted to a therapeutic community. *American Journal of Drug and Alcohol Abuse*, 26, 207–227.

Metrebian N, Shanahan W, Wells B, Stimson G (1998). Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions. *Medical Journal of Australia*, 168, 596–600.

Metzger DS, Woody GE, McLellan AT, O'Brien, CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E (1993). Human immunodeficiency virus seroconversion among intravenous drug users in and out of treatment: an 18-month prospective follow up. *AIDS*, 6, 1049–1056.

Miller CL, Tyndall M, Spittal P, Li K, Palepu A, Schechter MT (2002). Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchanges. *Journal of Urban Health*, 79, 257–265.

Miller WR (1983). ?????????? with problem drinkers. *Behavioural Psychotherapy*, 1, 147–172.

Miller WR, Leckman AL, Delaney HD, Tinkcom M (1992). Long-term follow-up of behavioural self-control training. *Journal of Studies on Alcohol*, 53, 249-261.

Miller WR, Rollnick S (1991). ?????????????? New York: Guilford.

Miller WR, Yahne C, Tonigan J (2003). ?????????????? in drug abuse services: a randomised trial. *Journal of Consulting and Clinical Psychology*, 71, 754-763.

Mills EJ, Wu P, Gagnier J, Ebbert JO (2005). Efficacy of acupuncture for cocaine dependence: a systematic review and meta analysis. *Harm Reduction Journal*, 2, 4.

Mitcheson M (1994). Drug clinics in the 1970s. In: Strang J, Gossop M, eds. *The British system* ?????????? London: Oxford University Press.

Mitcheson M, Edwards G, Hawks D, Ogborne A (1976). Treatment of methylamphetamine users during the 1968 epidemic. In: Edwards G, Russell M, Hawks D, MacCafferty M, eds. *Drugs and Drug Dependence*. Westmead: Saxon House.

Modesto-Lowe V, Kranzler H (1999). Using cue reactivity to evaluate medications for treatment of cocaine dependence: a critical review. *Addiction*, 94, 1639-1651.

Montgomery HA, Miller WR, Tonigan JS (1995). Does Alcoholics Anonymous involvement predict treatment outcome? *Journal of Substance Abuse Treatment*, 12, 241-246.

Moos RH (1997). *Evaluating Treatment Environments*. New Brunswick: Transaction.

Moos RH, Finney JW, Federman E, Suchinsky R (2000). Speciality mental health care improves patients' outcomes: findings from a nationwide program to monitor the quality of care for patients with substance use disorders. *Journal of Studies on Alcohol*, 61, 704-713.

Moos RH, Finney JW, Ouimette PC, Suchinsky R (1999). A comparative evaluation of substance abuse treatment: I. Treatment orientation, amount of care, and one year outcomes. *Alcoholism, Clinical and Experimental Research*, 23, 529-536.

Moos R, Schaefer J, Andrassy J, Moos B (2001). Outpatient mental health care, self-help groups, and patients' one-year treatment outcomes. *Journal of Clinical Psychology*, 57, 273-287.

Morgenstern J, Labouvie E, McCrady BS, Kahler CW, Frey RM (1997). Affiliation with Alcoholics Anonymous after treatment: a study of its therapeutic effects and mechanisms of action. *Journal of Consulting and Clinical Psychology*, 65: 768-777.

Myles J (1997). Treatment for amphetamine misuse in the United Kingdom. In: Klee H, ed. *Amphetamine Misuse*. Amsterdam: Harwood.

Najavits L, Weiss R (1994). Variations in therapist effectiveness in the treatment of patients with substance use disorders: an empirical review. *Addiction*, 89, 679-688.

National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. (1978). Clinical evaluation of naltrexone treatment of opiate dependent individuals. *Archives of General Psychiatry*, 35, 335-340.

Neeleman J, Farrell M (1997). Fatal methadone and heroin overdoses: time trends in England and Wales. *Journal of Epidemiology and Community Health*, 51, 435-437.

Noble A, Best B, Finch E, Gossop M, Sidwell C, Strang J (2000). Injecting risk behaviour and year of first injection as predictors of hepatitis B and C status among methadone maintenance patients in south London. *Journal of Substance Use*, 5, 131-135.

O'Brien C (1994). Opioids: Antagonists and Partial Antagonists. In: Galanter M, Kleber H, eds. *Textbook of Substance Abuse Treatment*. Washington: American Psychiatric Press.

O'Brien C, Childress A, McLellan A, Ehrman R (1990). Integrating systematic cue exposure with standard treatment in recovering drug dependent patients. *Addictive Behaviors*, 15, 355-365.

O'Brien C, Cornish J. (1999). Opioids: Antagonists and partial antagonists. In: Galanter M, Kleber H, eds. *Textbook of Substance Abuse Treatment*. 2nd ed. Washington: American Psychiatric Press.

O'Brien C, Greenstein R, Mintz J, Woody G (1975). Clinical experience with naltrexone. *American Journal of Drug and Alcohol Abuse*, 2, 365-377.

Ompad DC, Galea S, Wu Y, Fuller CM, Latka M, Koblin B, Vlahov D (2004). Acceptance and completion of hepatitis B vaccination among drug users in New York City. *Commun Dis Public Health*, 7, 294-300.

Orford J (2001). *Excessive appetites: a psychological view of addictions*. Chisester, New York: Wiley.

Orlinsky D, Roonnestad M, Willutzki U (2004). Fifty years of psychotherapy process-outcome research: continuity and change. In: Lambert MJ, ed. *Bergin and Garfield's Handbook of Psychotherapy and Behavior Change*. 5th ed. New York: John Wiley & Sons.

Otto KC, Quinn C, Sung YF (1998). Auricular acupuncture as an adjunctive treatment for cocaine addiction. A pilot study. *American Journal of Addiction*, 7, 164-170.

Ouimette P, Humphreys K, Moos R H, Finney J W, Cronkite R, Federman B (2001). Self help group participation among substance use disorder patients with post-traumatic stress disorder. *Journal of Substance Abuse Treatment*, 20, 25-32.

Ouimette P C, Finney J W, Moos R H (1997). Twelve step and cognitive behavioral treatment for substance abuse: a comparison of treatment effectiveness. *Journal of Consulting and Clinical Psychology*, 65, 230-240.

Ouimette PC, Moos RH, Finney JW (1998). Influence of outpatient treatment and Twelve-Step group involvement on one year substance abuse treatment outcomes. *Journal of Studies on Alcohol*, 59, 513-522.

Ouellet L, Huo D, Bailey SL (2004). HIV risk practices among needle exchange users and nonusers in Chicago. *Journal of Acquired Immune Deficiency Syndromes*, 37, 1187-1196.

Parsons J, Hickman M, Turnbull PJ, McSweeney T, Stimson GV, Judd A, Roberts K (2002). Over a decade of syringe exchange: results from 1997 UK survey. *Addiction*, 97, 845-850.

Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, Valla D, Erlinger S, Rueff B (1998). Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. *Hepatology*, 27, 1717-1722.

Peterson K, Swindle R, Phibbs C, Recine B, Moos R (1994). Determinants of readmission following inpatient substance abuse treatment. *Medical Care*, 32, 535-550.

Pfohl D, Allen J, Atkinson R, Knopman D, Malcolm R, Mitchell J, Morley J (1986). Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. Rockville, Maryland. NIDA Research Monograph No. 67, s. 66-72.

Powell J, Dawe S, Richards D, Gossop M, Marks I, Strang J, Gray J (1993). Can opiate addicts tell us about their relapse risk? Subjective predictors of clinical prognosis. *Addictive Behaviors*, 18, 473-490.

Powis B, Strang J, Griffiths P, Taylor C, Williamson S, Fountain J, Gossop M (1999). Self-reported overdose among injecting drug users in London: extent and nature of the problem. *Addiction*, 94, 471-478.

Prendergast ML, Podus D, Chang E, Urada D (2002). The effectiveness of drug abuse treatment: a meta analysis of comparison group studies. *Drug and Alcohol Dependence*, 67, 53-72.

Prendergast M, Wellisch J, Falkin G (1995). Assessment of and services for substance abusing women offenders in community and correctional settings. *Prison Journal*, 75, 240-256.

Reilly P M, Sees KL, Hall SM, Shropshire MS, Delucchi KL, Tusel, DJ, Banys P, Clark HW, Piotrowski NA (1995). Self-efficacy and illicit opioid use in a 180-day methadone detoxification treatment. *Journal of Consulting and Clinical Psychology*, 63, 158-162.

Resnick R, Schuyten-Resnick E, Washton A (1979). Narcotic antagonists in the treatment of opioid dependence: review and commentary. *Comprehensive Psychiatry*, 20, 116-125.

Rivara FP, Mueller BA, Somes G, Mendoza CT, Rushforth NB, Kellerman AL (1997). Alcohol and illicit drug abuse and the risk of violent death in the home. *Journal of the American Medical Association*, 278, 569-575.

Roberts K, Hunter C (2004). A comprehensive system of pharmaceutical care for drug misusers. *Harm Reduction Journal*, 1, 6.

Robles E, Silverman K, Preston K, Cone E, Katz E, Bigelow G, Stitzer M (2000). The brief abstinence test: voucher based reinforcement of cocaine abstinence. *Drug and Alcohol Dependence*, 58, 205-212.

Robles E, Silverman K, Stitzer M (1999). Contingency management therapies. In: Strain E, Stitzer M, eds. *Methadone Treatment for Opioid Dependence*. Baltimore: Johns Hopkins University Press.

Rohsenow DJ, Monti PM, Martin RA, Colby SM, Myers MG, Gulliver SB, Brown RA, Mueller TI, Gordon A, Abrams DB (2004). Motivational enhancement and coping skills training for cocaine abusers: effects on substance use outcomes. *Addiction*, 99, 862-874.



Rollnick S (2001). Enthusiasm, quick fixes and premature controlled trials. *Addiction*, 96, 1769–1775.

Rosenblum A, Magura S, Foote J, Palij M, Handelsman L, Lovejoy M. and Stimmel B (1995). Treatment intensity and reduction in drug use for cocaine-dependent methadone patients: a dose-response relationship. *Journal of Psychoactive Drugs*, 27, 151–159.

Rossow I, Lauritzen G (1999). Balancing on the edge of death: suicide attempts and life-threatening overdoses among drug addicts. *Addiction*, 94, 209–219.

Rounsaville BJ (1995). Can psychotherapy rescue naltrexone treatment of opioid addiction? In: Onken L, Blaine J, Boren J, eds. *Integrating behavioral therapies with medications in the treatment of drug dependence*. NIDA Monograph No.150. Rockville, MD: NIDA.

Rounsaville BJ, Kosten T, Weissman M, Kleber H (1986). Prognostic significance of psychopathology in treated opiate addicts. *Comprehensive Psychiatry*, 27, 480–498.

Saunders B, Wilkinson C, Philips M (1995). The impact of a brief motivational intervention with opiate users attending a methadone programme. *Addiction*, 90, 415–424.

Saxon A, Wells E, Fleming C, Jackson R, Calsyn D (1996). Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. *Addiction*, 91, 1197–1209.

Schechter MT, Strathdee SA, Cornelisse PG, Currie S, Patrick DM, Rekart ML, O'Shaughnessy MV (1999). Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. *AIDS*, 13, 45–51.

Schmitz JM, Oswald LM, Jacks SD, Rustin T, Rhoades HM, Grabowski J (1997). Relapse prevention treatment for cocaine dependence: group versus individual format. *Addictive Behaviors*, 22, 405–418.

Schoenbaum EE, Hartel DM, Gourevitch MN (1996). Needle exchange use among a cohort of injecting drug users. *AIDS*, 10, 1729–1734.

Schuckit MA, Hesselbrock V (1994). Alcohol dependence and anxiety disorders: what is the relationship? *American Journal of Psychiatry*, 151, 1723–1734.

Schut J, Wohlmuth T, File K (1973). Low dosage maintenance: a re-examination. *International Journal of Clinical Pharmacology and Toxicology*, 7, 48–53.

Scott J, Gilvarry E, Farrell M (1998). Managing anxiety and depression in alcohol and drug dependence. *Addictive Behaviors*, 23, 919–931.

Sees K, Delucchi K, Masson C, Rosen A, Westley Clark H, Robillard H, Banys P, Hall S (2000). Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. *Journal of the American Medical Association*, 283, 1303–1310.

Seivewright N (2000). *Community Treatment of Drug Misuse: More than Methadone*. Cambridge: Cambridge University Press.

Sell L, Farrell M, Robson P (1997). Prescription of diamorphine, dipipanone and cocaine in England and Wales. *Drug and Alcohol Review*, 16, 221–226.

Sell L, Segar G, and Merrill J (2001). One hundred and twentyfive patients prescribed injectable opiates in the north west of England. *Drug and Alcohol Review*, 20, 57–66.

Selwyn P, Feiner C, Cox C, Lipshutz C, Cohen R (1987). Knowledge about AIDS and high risk behavior among intravenous drug users in New York City. *AIDS*, 1, 247–254.

Shearer J, Wodak A, Mattick R, van Beek I, Lewis J, Hall W, Dolan K (2001). Pilot randomised controlled study of dexamphetamine substitution for amphetamine dependence. *Addiction*, 96, 1289–1296.

Sheridan J, Lovell S, Turnbull P, Parsons J, Stimson G, Strang J (2000). Pharmacy-based needle exchange (PBNX) schemes in south east England: a survey of service providers. *Addiction*, 95, 1551–1560.

Sibthorpe B, Fleming D, Gould J (1994). Self-help groups: a key to HIV risk reduction for high-risk injection drug users? *Journal of Acquired Immune Deficiency Syndromes*, 7, 592–598.

Silverman K, Chutuape M, Bigelow G, Stitzer M (1996). Voucher based reinforcement of attendance by unemployed methadone patients in a job skills training program. *Drug and Alcohol Dependence*, 41, 197–207.

Simpson DD (1981). Treatment for drug use: follow-up outcomes and length of time spent. *Archives of General Psychiatry*, 38, 875–880.

Simpson DD (1997). Effectiveness of drug abuse treatment: a review of research from field settings. In: Egerton JA, Fox DM, Leshner AI, eds. *Treating Drug Abusers Effectively*. Oxford: Blackwell.

Simpson DD (2002). A conceptual framework for transferring research to practice. *Journal of Substance Abuse Treatment*, 22, 171–182.

Simpson DD (2004). A conceptual framework for drug treatment process and outcomes. *Journal of Substance Abuse Treatment*, 27, 99–121.

Simpson DD, Joe GW, Broome KM (2002). A national five-year follow-up of treatment outcomes for cocaine dependence. *Archives of General Psychiatry*, 59, 538–544.

Simpson DD, Joe G, Brown B (1997). Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). *Psychology of Addictive Behaviors*, 11, 294–307.

Simpson DD, Joe GW, Fletcher BW, Hubbard RL, Anglin MD (1999). A national evaluation of treatment outcomes for cocaine dependence. *Archives of General Psychiatry*, 56, 507–514.

Simpson DD, Joe G, Rowan-Szal G, Greener J (1995). Client engagement and change during drug abuse treatment. *Journal of Substance Abuse*, 7, 117–134.

Simpson DD, Joe GW, Rowan-Szal GA, Greener JM (1997). Drug abuse treatment process components that improve retention. *Journal of Substance Abuse Treatment*, 14, 565–572.

Simpson DD, Lloyd MR (1981). Alcohol use following treatment for drug addiction: a four-year follow-up. *Journal of Studies on Alcohol*, 42: 323–335.

Simpson D, Savage L (1980). Drug abuse treatment readmissions and outcomes. *Archives of General Psychiatry*, 37, 896–901.

Simpson D, Savage L, Lloyd M (1979). Follow-up evaluation of treatment of drug abuse during 1969–1972. *Archives of General Psychiatry*, 36, 772–780.

Simpson D, Sells S (1983). Effectiveness for treatment of drug abuse: an overview of the DARP research programme. *Advances in Alcohol and Substance Abuse*, 2, 7–29.

Sinha R, Easton C, Renee-Aubin L, Carroll KM (2003). Engaging young probation-referred marijuana-abusing individuals in treatment: a pilot trial. *American Journal of Addictions*, 12, 314–323.

Sobell M, Sobell L (1999). Stepped care for alcohol problems: an efficient method for planning and delivering clinical services. In: Tucker J, Donovan D, Marlatt GA, eds. *Changing Addictive Behavior*. New York: Guilford.

Sorensen JL, Copeland AL (2000). Drug abuse treatment as an HIV prevention strategy: a review. *Drug Alcohol Dependence*, 59, 17–31.

Steinberg KL, Roffman RA, Carroll KM, Kabela E, Kadden R, Miller M, Duresky D (2002). Tailoring cannabis dependence treatment for a diverse population. *Addiction*, 97, 135–142.

Stephens RS, Roffman R, Curtin L (2000). Comparison of extended versus brief treatments for marijuana use. *Journal of Consulting and Clinical Psychology*, 68, 898–908.

Stimson G (1995). AIDS and injecting drug use in the United Kingdom, 1987–1993: the policy response and the prevention of the epidemic. *Social Science and Medicine*, 41, 699–716.

Stimson G, Alldritt L, Dolan K, Donoghoe M (1988). Syringe exchange schemes for drug users in England and Scotland. *British Medical Journal*, 296: 1717.

Stimson G, Donoghoe M, Lart R, Dolan K (1990). Distributing sterile needles and syringes to people who inject drugs: the syringe exchange experiment. In: Strang J, Stimson G, eds. *AIDS and Drug Misuse*. London: Routledge.

Stitzer M, Bickel W, Bigelow G, Liebson I (1986). Effect of methadone dose contingencies on urinalysis test results of polydrug abusing methadone maintenance patients. *Drug and Alcohol Dependence*, 18, 341–348.

Stitzer M, Bigelow G, Gross J (1989). Behavioral treatment of drug abuse. In: Karasu TB, ed. *Treatments of Psychiatric Disorders: a Task Force Report of the American Psychiatric Association*. Vol. 2. Washington: American Psychiatric Association.

Stitzer M, Bigelow G, Lawrence C, Cohen J, D'Lugoff B, Hawthorne J (1977). Medication take home as a reinforcer in a methadone maintenance program. *Addictive Behaviors*, 2, 9–14.



Stitzer M, Bigelow G, Liebson I, Hawthorne J (1982). Contingent reinforcement of benzodiazepine-free urines. *Journal of Applied Analysis of Behavior*, 15, 493-503.

Stone E, Fletcher K (2003). User views on supervised methadone consumption. *Addict Biol*, 8, 45-48.

Stephens RS, Roffman RA, Curtin L (2000). Comparison of extended versus brief treatments for marijuana use. *Journal of Consulting and Clinical Psychology*, 68, 898-908.

Stephens RS, Roffman RA, Fearer SA, Williams C, Picciano JF, Burke RS (2004). The marijuana check-up: reaching users who are ambivalent about change. *Addiction*, 99, 1323-1332.

Sterling RC, Gottheil E, Weinstein SP, Serota R (2001). The effect of therapist/patient race- and sex-matching in individual treatment. *Addiction*, 96, 1015-1022.

Stewart D, Gossop M, Marsden J (2004). Increased caseloads in methadone treatment programs: implications for the delivery of services and retention in treatment. *Journal of Substance Abuse Treatment*, 27, 301-306.

Stewart D, Gossop M, Marsden J, Rolfe A (2000). Drug misuse and acquisitive crime among clients recruited to the National Treatment Outcome Research Study (NTORS). *Criminal Behaviour and Mental Health*, 10, 10-20.

Stewart D, Gossop M, Marsden J, Strang J (2000b). Variation between and within drug treatment modalities: data from the National Treatment Outcome Research Study (UK). *European Addiction Research*, 6, 106-114.

Stewart D, Gossop M, Marsden J, Kidd T, Treacy S (2003). Similarities in outcomes for men and women after drug misuse treatment: results from the National Treatment Outcome Research Study (NTORS). *Drug and Alcohol Review*, 22, 35-41.

Stotts AL, Schmitz JM, Rhoades HM, Grabowski J (2001). with cocaine-dependent patients: A pilot study. *Journal of Consulting and Clinical Psychology*, 69, 858-862.

Strain EC (1999). Methadone dose during maintenance treatment. In: Strain E, Stitzer M, eds. *Methadone Treatment for Opioid Dependence*. Baltimore: Johns Hopkins.

Strain EC, Bigelow G, Liebson I, Stitzer M (1999). Moderate versus high-dose methadone in the treatment of opioid dependence. *Journal of the American Medical Association*, 281, 1000-1005.

Strain EC, Brooner RK, Bigelow GE (1991). Clustering of multiple substance use and psychiatric diagnoses in opiate addicts. *Drug & Alcohol Dependence*, 27, 127-134.

Strain EC, Stoller KB (1999). Introduction and historical overview. In: Strain E, Stitzer M, eds. *Methadone Treatment for Opioid Dependence*. Baltimore: Johns Hopkins.

Strang J, Bearn J, Gossop M (1997a). Opiate detoxification under anaesthesia. *British Medical Journal*, 315, 1249-1250.

Strang J, Bearn J, Gossop M (1999). Lofexidine for opiate detoxification: review of recent randomised and open trials. *American Journal on Addictions*, 8, 337-348.

Strang J, Finch E, Hankinson L, Farell M, Taylor C, Gossop M (1997). Methadone treatment for opiate addiction: benefits in the first month. *Addiction Research*, 5, 71-76.

Strang J, Gossop M (1990). Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts. *Addictive Behavior*, 15, 541-547.

Strang J, Griffiths P, Abbey J, Gossop M (1994). Survey of use of injected benzodiazepines among drug users in Britain. *British Medical Journal*, 308, 1082.

Strang J, Griffiths P, Powis B, Fountain J, Williamson S, Gossop M (1999a). Which drugs cause overdose among opiate misusers? Study of personal and witnessed overdoses. *Drug and Alcohol Review*, 18, 253-261.

Strang J, Marsden J, Cummins M, Farrell M, Finch E, Gossop M, Stewart D, Welch S (2000). Randomised trial of supervised injectable versus oral methadone maintenance: report of feasibility and six-month outcomes. *Addiction*, 95, 1631-1645.

Strang J, Powis B, Best D, Vingoe L, Griffiths P, Taylor C, Welsh S, Gossop M (1999). Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. *Addiction*, 94, 199-204.

Strang J, Powis B, Griffiths P, Gossop M (1996). The bettertravelled treatment tourist: service overlap among heroin and cocaine users. *Druglink*, 11, 10–13.

Strang J, Sheridan J (1997). Prescribing amphetamines to drug misusers: data from the 1995 national survey of community pharmacies in England and Wales. *Addiction*, 92, 833–838.

Strang J, Sheridan J (1998). National and regional characteristics of methadone prescribing in England and Wales: local analyses of data from the 1995 national survey of community pharmacies. *Journal of Substance Misuse*, 3, 240–246.

Strang J, Sheridan J, Barber N (1996). Prescribing injectable and oral methadone to opiate addicts: results from the 1995 national postal survey of community pharmacies. *British Medical Journal*, 313, 270–272.

Swift R, Miller N (1997). Integration of health care economics for addiction treatment in clinic care. *Journal of Psychoactive Drugs*, 29, 255–262.

Tennant FS, Rawson RA, Cohen AJ, Mann A (1984). Clinical experience with naltrexone in suburban opioid addicts. *Journal of Clinical Psychiatry*, 45, 41–45.

Thirion X, Lapierre V, Micallef J, Ronflé E, Masutb A, Pradela, Coudertb C, Mabriez J, Sanmarco J (2002). Buprenorphine prescription by general practitioners in a French region. *Drug and Alcohol Dependence*, 65, 197–204.

Thornton CC, Gottheil E, Weinstein SP, Kerachsky RS (1998). Patient-treatment matching in substance abuse. Drug addiction severity. *Journal of Substance Abuse Treatment*, 15, 505–511.

Toumbourou JW, Hamilton M, U'Ren A, Stevens-Jones P, Storey G (2002). Narcotics Anonymous participation and changes in substance use and social support. *Journal of Substance Abuse Treatment*, 23, 61–66.

Tucker T, Fry CL, Lintzeris N, Baldwin S, Ritter A, Donath S, Whelan G (2004). Randomised controlled trial of a brief behavioural intervention for reducing hepatitis C virus risk practices among injecting drug users. *Addiction*, 99, 1157–1166.

Tucker T, Ritter A, Maher C, Jackson H (2004). Naltrexone maintenance for heroin dependence: uptake, attrition and retention. *Drug and Alcohol Review*, 23, 299–309.

Uchtenhagen A, Dobler-Mikola A, Steffan T, Gutzwiller F, Blattler R, Pfeifer S (1999). Prescription of Narcotics for Heroin Addicts. Basek: Karger.

Unnithan S, Gossop M, Strang J (1992). Factors associated with relapse among opiate addicts in an out-patient detoxification programme. *British Journal of Psychiatry*, 161, 654–657.

van den Brink W, Hendriks V, Blanken P, Huijsman I, van Ree J (2002). Medical co-prescription of heroin: two randomised controlled trials. Utrecht: CCBH.

Vignau J, Duhamel A, Catteau J, Legal G, Huynh Pho A, Grailles I, Beauvillain J, Petit P, Beauvillain P, Parquet P (2001). Practicebased buprenorphine maintenance treatment (BMT): how do French health-care providers manage the opiate-addicted patients? *Journal of Substance Abuse Treatment*, 21, 135–144.

Ward J, Mattick R, and Hall W (1992). Key Issues in Methadone Maintenance Treatment. Sydney: New South Wales Press.

Ward J, Mattick R, Hall W (1998). Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Harwood, Australia.

Washburn A, Fullilove R, Fullilove M, Keenan P, McGee B, Morris K, Sorensen J, Clark W (1993). Acupuncture heroin detoxification: a single-blind clinical trial. *Journal of Substance Abuse Treatment*, 10, 345–351.

Washton A, Pottash A, Gold M (1984). Naltrexone in addicted business executives and physicians. *Journal of Clinical Psychiatry*, 49, 39–41.

Weiss RD, Griffin ML, Gallop R, Onken LS, Gastfriend DR, Daley D, Crits-Christoph P, Bishop S, Barber JP (2000). Self-help group attendance and participation among cocaine dependent patients. *Drug Alcohol Dependence*, 60, 169–177.



Weiss RD, Griffin ML, Najavits LM, Hufford C, Kogan J, Thompson HJ, Albeck JH, Bishop S, Daley DC, Mercer D, Siqueland L (1996). Self-help activities in cocaine dependent patients entering treatment: results from NIDA collaborative cocaine treatment study. *Drug and Alcohol Dependence*, 43, 79.

Weiss RD, Griffin ML, Gallop RJ, Najavits LM, Frank A, Crits-Christoph P, Thase ME, Blaine J, Gastfriend DR, Daley D, Luborsky L (2005). The effect of Twelve-Step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. *Drug and Alcohol Dependence*, 77, 177–184.

Wells EA, Peterson PL, Gainey RR, Hawkins JD, Catalano RF (1994). Outpatient treatment for cocaine abuse: a controlled comparison of relapse prevention and twelve-step approaches. *American Journal of Drug and Alcohol Abuse*, 20, 1–17.

Wexler H, Melnick G, Lowe L, Peters J (1999). Three-year incarceration outcomes for amity in-prison therapeutic community and aftercare in California. *Prison Journal*, 79, 321–336.

White R, Alcorn R, Feinmann C (2001). Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. *Drug and Alcohol Dependence*, 65, 77–83.

Williams AB, McNelly EA, Williams AE, D'Aquila RT (1992). Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. *AIDS Care*, 4, 35–41.

Williams H (1971). Low and high dose methadone maintenance in the outpatient treatment of the hard-core heroin addict. In: Einstein S, ed. *Methadone Maintenance*. New York: Marcel Dekker.

Williams RJ, Chang SY (2000). A comprehensive and comparative review of adolescent substance abuse treatment outcome. *Clinical Psychology and Sci Practice*, 7, 138–166.

Wilson B, Elms R, Tompson C (1975). Outpatient versus hospital methadone detoxification: experimental comparison. *International Journal of the Addictions*, 10, 13–21.

Wilson GT (1996). Treatment manuals in clinical practice. *Behaviour Research and Therapy*, 34, 295–314.

Winick C (1990–1991). The counsellor in drug abuse treatment. *International Journal of the Addictions*, 25, 1479–1502.

Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, Tyndall MW (2004). Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. *CMAJ*, 171, 731–734.

Wood E, Tyndall MW, Spittal P, Li K, Hogg R, O'Shaughnessy M, Schechter M (2002). Needle exchange and difficulty with needle access during an ongoing HIV epidemic. *International Journal of Drug Policy*, 13, 95–102.

Woody G, McLellan AT, Luborsky L (1984). Psychiatric severity as a predictor of benefits from psychotherapy. *American Journal of Psychiatry*, 141, 1171–1177.

Woody G, McLellan AT, Luborsky L, O'Brien C (1987). Twelvemonth follow-up of psychotherapy for opiate dependence. *American Journal of Psychiatry*, 144, 38–46.

Woody G, McLellan AT, Luborsky L, O'Brien C, Blaine J, Fox S, Herman I, Beck A (1984). Severity of psychiatric symptoms as a predictor of benefits from psychotherapy: the Veterans Administration-Penn Study. *American Journal of Psychiatry*, 141, 1172–1177.

Wutzke S, Conigrave K, Saunders J, Hall W (2002). The longterm effectiveness of brief interventions for unsafe alcohol consumption: a ten-year follow-up. *Addiction*, 97, 665–675.

Yancovitz S, DesJarlais D, Peyser N (1991). A randomised trial of an interim methadone clinic. *American Journal of Public Health*, 81, 1185–1191.

Zhang Z, Friedmann PD, Gerstein DR (2003). Does retention matter? Treatment duration and improvement in drug use. *Addiction*, 98, 673–684.